Saturday, 24 February 2018

Results of 2nd Annual Pharma Literati Contest

Pharma Literati had announced the 2nd annual Pharma Literati essay contest. In last few days, all the essays are published. 

The results for the contest are based on the originality of the content, relevance of the topics, language and essay guidelines as provided.

1. The first winner is Yash Nandwani from NIPER, Mohali for essay titled, "Indian Pharma Industry: Changing dynamics."

2. The second winner is Babita Sarangi from Department of Pharmacy, Annamalai University, Annamalai Nagar, Tamilnadu for essay titled, "Entrepreneurship scenario after Pharmacy education" .

3. The third winner is M. Karthika from Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode for essay titled, ""Entrepreneurship scenario after Pharmacy education".

Congratulations to all the winners. They would receive separate email in next few days for the prize. Others can send an email to


The pharmaceutical industry is changing and traditional paths to innovation are no longer suitable. A drastically different reimbursement climate, the growing interest in biologic drugs, the shift from blockbusters to niche medicines, and the differing needs of emerging markets all have affected the cost structure and profitability of drug manufacturers, which is in turn affecting R&D needs and capabilities. Successful pharmaceutical companies have developed innovation networks including varying external groupsfrom insurance companies to academic medical centersto support the discovery, development, and commercialization of new therapies.

The Pharmaceutical industry does not create cures, they create customers.”


Traditional models
The historical innovation pathway for pharmaceutical companies has involved the development of small-molecule drugs following an integrated model.For many years, pharmaceutical companies leveraged organic chemistry-based research and manufacturing, and with government support for intensified R&D programs that facilitated the application of microbiology, enzymology, and biochemistry, built the capability to produce and sell prescription drugs to doctors and hospitals. As a result, pharmaceutical companies became very large, highly integrated organizations with R&D, manufacturing, marketing, and distribution capabilities that were very R&D-intensive and innovative, focusing on target-based drug discovery.

Need for change
Competition from low-priced generics, demands from consumers and other payers, changing government policies particularly with respect to reimbursement, the needs of emerging markets, spiraling R&D costs, and declining R&D productivity are all affecting the ability of drug manufacturers to innovate and deliver value.
Weak regulatory controls and intellectual property protection, a lack of health insurance programs, and the much reduced per capita drug spend in emerging markets all affect innovation to some degree.
The open innovation model
To create value under these changing market conditions, Big Pharma companies are adopting an open innovation model in which value creation is achieved by exploiting evolving scientific and technological knowledge from a vast array of sources, including academic researchers, other biotechnology and pharmaceutical companies, government institutes, independent innovation centers, consultants, and even companies in other industries.
The rise of the academic medical center
One type of external resource that pharmaceutical companies are increasingly turning to is academic medical centers that offer a range of support, from basic research to technology development to specialized services.
Academic medical centers such as the one at Wake Forest are attractive to industry because they have a large knowledge base and expertise, and often, established contacts already exist between faculty members and industry. What is changing is the extent of support that these centers can provide to a pharmaceutical company in terms of taking fundamental discoveries and converting them into commercial products that can benefit patients.

Meeting patient needs

Because the mission of both the pharmaceutical industry and academic medical centers is to cure diseases and improve patient lives, growing opportunities to work with industry in numerous areas of innovation.Academic medical centers, with their large knowledge bases and ability to convert basic findings into commercial products, will play a critical role in getting new drugs to patients.

The Indian pharmaceutical industry is a success story providing employment for millions and ensuring that essential drugs at affordable prices are available to the vast population of this sub-continent.”
-Richard Gerster



India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. Between September 2008 and September 2009, the total turnover of India's pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually.

It is clear that the pharmaceutical industry is not, by any stretch of the imagination, doing enough to ensure that the poor have access to adequate medical care.


In the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxy followed next. The highest growth was for Mankind Pharma (37.2%). Other leading companies in the Indian pharma market in 2010 are:
o   Sun Pharma (25.7%)
o   Abbott (25%)
o   Zydus Cadila (24.1%)
o   Alkem Laboratories (23.3%)
o   Pfizer (23.6 %)
o   GSK India (19%)
o   Piramal Healthcare (18.6 %)
o   Lupin (18.8 %)

v  The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6 billion in 2009. Due to increase in the population of high income group, there is every likelihood that they will open a potential US$ 8 billion market for multinational companies selling costly drugs by 2015.Thus India would really become a lucrative destination for clinical trials for global giants. 
v  There was another report by RNCOS titled "Booming Pharma Sector in India" in which it was projectedt that thepharmaceutical formulations industry is expected to prosper in the same manner as the pharmaceutical industry. The domestic formulations market will grow at an annual rate of around 17% in 2010-11, owing to increasing middle class population and rapid urbanisation.


v The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units.It is an extremely fragmented market with severe price competition and government price control.
v The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. There are about 250 large units and about 8000 Small Scale Units.These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulation.
v Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market. 


Competent workforce: India has a pool of personnel with high managerial and technical competence as also skilled workforce. It has an educated work force and English is commonly used. Professional services are easily available.

Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk drugs.

Legal & Financial Framework: India has a 53 year old democracyand hence has a solid legal framework and strong financial markets. There is already an established international industry and business community.

Information & Technology: It has a good network of world-class educational institutions and established strengths in Information Technology.

Globalization: The country is committed to a free market economy and globalization. Above all, it has a 70 million middle class market, which is continuously growing.

Consolidation: For the first time in many years, the international pharmaceutical industry is finding great opportunities in India. The process of consolidation, which has become a generalized phenomenon in the world pharmaceutical industry, has started taking place in India. 



v  Indian companies need to attain the right product-mix for sustained future growth. Core competencies will play an important role in determining the future of many Indian pharmaceutical companies in the post product-patent regime after 2005.
v  Indian companies, in an effort to consolidate their position, will have to increasingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D efforts and improve distribution to penetrate markets. 
v  Research and development has always taken the back seat amongst Indian pharmaceutical companies. In order to stay competitive in the future, Indian companies will have to refocus and invest heavily in R&D. 
v  The Indian pharmaceutical industry also needs to take advantage of the recent advances in biotechnology and information technology. The future of the industry will be determined by how well it markets its products to several regions and distributes risks, its forward and backward integration capabilities, its R&D, its consolidation through mergers and acquisitions, co-marketing and licensing agreements.

Indias Pharmaceutical industry is on a good growth path, but will have to watch out for the regulatory interventions”.

Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world. 

The key change in todays pharmaceutical industry is that the value of pharmaceutical innovation is no longer embodied in new drugs and new markets alone, nor is it commanded by pharmaceutical companiesBig Pharmas success with respect to innovation lies in finding ways to capture value based on these market opportunities and requires a shift from product-centric innovation towards market-centric innovation.

Indian Pharma Industry: Changing Dynamics_An essay by Yash Nandwani

Hippocrates, the father of medicine once foretold that there would come a time when “Medicine would be thy food and food will be thy medicine”. We are certainly witnessing that era, as mankind has become greatly dependent on drugs for its survival be it-Natural Products, Pharmaceuticals or Biologicals. We have come way ahead of the times of Galen, who produced the first cold cream to modern medicines that involve complex mechanism of actions requiring a very dedicated research. In order to understand the ever changing dynamics of the pharma industry, we need to first look into what got us to this pinnacle which we have achieved in these years. Firstly, Drugs and Cosmetics Act was enacted in 1940 that lead to the modernization of the industry for the first time, simultaneously; developments such as Federal Food, Drug, and Cosmetic Act (FD&C Act) in the US changed how drugs were administered. Secondly, the tragedy of thalidomide shook the world which led to extensive requirement of safety parameters of new drugs, further accelerating the development of Hatch Waxman Act that balanced the power tussle between the innovator and the generic manufacturers. Patents Act of 1970 and subsequent amendments in 2005 with respect to TRIPS agreement led to the end of process patents that served as a boon for the pharma industry as it protected both the product as well as process of drug manufacture from infringement and promoted cross-licensing of the formulation. Furthermore, the clause of compulsory licensing in the worst case scenario such as patent abuse by innovator as well as in case of national emergency infused trust in the lacs of patients requiring life saving drugs in their treatment course.

The pharmaceutical industry, as we all know, is involved in formulation of large scale of quality dosage forms which may seem as a solely profit-oriented field - “The BIG PHARMA” to the public, but one should keep in mind the billions of dollars spent on research and development of newer better drugs with various kinds of formulation technology- Nanotechnology and Biotechnology. Research involves the blood, sweat, toil, and tears of pharmacists which begins with synthesis and high throughput screening of the plethora of compounds by medicinal chemists, later giving them structural modifications to give a good lead compound. Once all this is established, it involves the hardwork of formulation scientists to convert lead into a suitable dosage that is mass-producible and patient compliant. Moreover, robust documentation and marketing of a drug is also carried out considering it as an essential part in the lifecycle of a product. It finally ends up at the community pharmacist who is directly interacting with the patient. Thus, this network of pharmacists of various fields forms an indisposable link which holds together the discipline of modern medicine.

In light of the new laws being framed, Drug Price Control Order (DPCO) 2013 is a game-changing tool which has brought around 640 drugs in the ambit of price control under scheduled drugs and formulations which some consider as a bane to the MNCs as the margins are fixed according to the market players dealing with a similar product leading to lower profits. All things considered, it seems reasonable to assume that the Indian pharmaceutical industry will grow at a CAGR of 15% in the next 10 years which includes both API coupled with formulations. India being a semi-regulated market is focussing on better laws which compel the manufacturer to follow GMP, GLP, as given in schedule M and ICH. Moreover, the increase in harmonization due to efforts of the US, EU, and Japan, is causing the other markets to tend towards a nearly ideal situation. On the other hand, the development of National List of Essential Medicines (NLEM), similar to the WHO list, is an applaudable job done by the National Pharmaceutical Pricing Authority(NPPA). Also, documents such as guidance to the industry are worth mentioning as the recommendations given in them are a useful requirement for getting to know newer technology which FDA is focusing on.

Indian pharma is taking huge leaps of success with its futuristic approach involving - novel drug delivery systems, mobile based applications, precision drug delivery and patient-specific drug delivery which includes optimization according to the need. Having said that, India can be truly considered as the future pharma capital of the world given the fact that a high number of quality medicines are being produced at a very low cost. In comparison to other countries, India bagged almost 40% of the ANDA approvals due to the aggressive filing of dossiers. Also, Para IV filing which offers market exclusivity for 180 days is being utilized as an effective tool in combating competition. It is worth mentioning that although market exclusivity for the firm will be offered; filing by many parties on the same day can lead to shared exclusivity which gives the sense of competition in the pharma industry. Significantly, as a result of patent cliff and patent expiration of a majority of innovator compounds, the potential for growth is multifold and opportunities are immense. India has an enormous potential given the fact that setup of plant and labour costs are very less, and the academic base of people is strong with the technical skill set required for jobs.

Now, as we have seen, the pharma industry can be considered to be a farrago of complexities with so many players in the organized as well as unorganized sectors. The growth of contract research and manufacturing service companies (CRAMS), together with clearing and forwarding agents (CFA), is the evidence to the paradigm shift of the MNCs towards just marketing of the product rather than full-scale manufacture by outsourcing various activities although, still maintaining profits higher than their counterparts. Then again, the services offered by research organizations have an additional advantage owing to the high amount of English speaking manpower when compared to China in the service sector. Moreover, Pharmacy Act, 1948 has regularised education to a large extent, increasing academia related technology transfer, which is playing an important role in the complete 360ยบ development of the industry.

Another advancement is the growth of continuous manufacturing lines undergoing a transition from the traditional batch processing such as GEA Continuous Tableting Line in compliance with Good Automated Manufacturing Practices (GAMP) has cut down labour to a maximum extent, decreased the time (20mins from API to Tablet) and improved efficiency of methods. The implementation of socioeconomic zones (SEZ) caused nullification of excise duty leading to a win-win situation for both employer and employees in underdeveloped regions. However, with the GST regime in place, it has steered us towards a level playing field for all. Retail pharmacies are surging on e-platforms improving their customer base and reliability thanks to the door-to-door services that they offer at affordable rates. India remains a “to go” destination for clinical trials with a wide variety of human resource pool galvanized with a large number of GCP/GLP approved bodies for carrying out trials in an ethical manner.

Meanwhile, Indian exports consisting of a myriad of products ranging from vaccines to medical devices has spiralled simultaneously, with the setting up of units in African and south-east Asian countries. On the contrary, imports just remain confined to certain essential API such as vitamins and antibiotics, which the government is planning to reduce by providing incentives to fermentation setups. The CDSCO in its new draft policy, along with state and central machinery is planning to introduce BA/BE studies for all generics, which will be a commendable step in the direction of compliance with international standards of production. As we are moving towards an era of innovation and novelty, the rise in the number of startups is catapulting growth in healthcare sector such as the insurance field. Another key development is in the field of low-cost research and development by foreign companies taking benefit of 100% Foreign Direct Investment(FDI) in greenfield and 74% in brownfield pharma, thereby boosting mergers and acquisitions along with private equity investments.

One more reason to these changing dynamics is the enormous transformation of the mindset of pharma community adhering to values and strong rules which abolished the release of counterfeit and Non-Standard Quality (NSQ) drugs that were a menace during the early times of implementation of policy. On the other hand, intellectual property management is what is making the difference between the good and excellent, as marketing in terms of trademarks, copyright, and patents is the driving force in today’s economic scenario. Now, a time has come where people buy drugs with the same caution as they would buy any other thing, as people are aware of what is generic and what is called to be a branded product. Gone are the days when Indian pharma was looked down upon as a speck of dust which now after decades of improvement, is shining as bright as the North Star.

To give an illustration, Indian pharma sector is poised to grow at a humongous rate with its patent, price and quality model which is at a very advantageous situation when compared to other countries. Truly, India can be considered as the “Pharmacy of the developing world” owing to its strong organization which acts as a buffer to inflation. And even when other sectors might be affected, the pharma industry remains strong as ever. Likewise, red tape prevailing in the DCGI office has been minimised and NDA approvals are faster; generic substitutions are allowed while doctors have been provided incentives to prescribe generic instead of costly branded drugs. The widespread rumour that small and medium scale units cannot match international standards is being squashed time and again and stereotyping of the Indian methods is plummeting at the global level. Furthermore, institutions such as Bulk Drug Manufacturers Association India (BDMAI) and Indian Pharmaceutical Association (IPA) are strengthening the core roots of Indian pharma. Additionally, the recent release of Indian Pharmacopoeia 2018 with updates to monographs and amendments is improving the quality of the finished product.

The field of biosimilars is trending upwards while pseudogeneric filing and patent evergreening is being nipped in the bud by authorities combined with the genesis of consumer activism. Yet, there are a few concerns such as surprise checks being done by the USFDA on units which can be termed as harsh, as well as prejudiced in nature. Furthermore, Indian pharma sector is seen as a highly fragmented niche overloaded with generic producers, leading to a topsy-turvy situation. Also, there is a pretty high amount of corruption in the procurement of drugs by public sector undertakings as well as improper government tenders which is a serious challenge to look forward to. The recent Pharmacy Practice Regulations, 2015, has brought in penalties for malpractices carried out in the retail units. It has restricted one pharmacist to only one pharmacy and focussed on improving ethics. That said, one cannot underestimate the hidden potential of Indian manufacturers which is like an iceberg that looks small superficially, but is immensely gigantic underneath. One must not forget the contributions made by stalwarts such as Prafulla Chandra Ray who set up Bengal chemicals and pharmaceuticals in 1901 and ML Shroff who laid the foundation of what we call now as “The Indian Advantage”- The Indian Pharma Industry; which is a self-sufficient entity fulfilling needs of the entire humanity. With changing times and increased number of diseases, revolutionary reforms are needed arising from the source trickling down to the consumer, only possible through maintaining a positive mindset, thus terming Indian pharma industry as a constructive “BETTER PHARMA”, rather than the capitalistic “BIG PHARMA”.


          In this world of specialization and globalization the Pharmacy education is suffering from serious backdrops and flaws. The potentials for growth of Pharmacy profession is enormous, if we are prepared to upgrade our standards to international and global expectations.  The Education Regulation of PCI which governs diploma education in India has not undergone any updation since 20 years. The students are still getting the 20-30 yrs older compounding practical exposure in labs during the graduation level. The current frame work of Pharmacy education in India produces outdated and unskilled professionals. The products of this form of education lack the much needed professionalism and rational thinking. 4 yrs of education in graduation level does not even make them fit for dispensing drugs confidently in a drug store. This is one of the main reasons behind Pharmacy being an under developed profession in India. We also suggest the application of TQM and innovation ecosystems in Pharmacy education. We urge all the pharmacists to be a part and parcel of this rejuvenation process. The mushrooming growth of Pharmacy colleges in India has contributed to the deterioration of in the standards of Pharmacy education in India. It has become obligatory that the Pharmacy colleges have to improve their status to sustain their existence.

The primary goal of anyone working in Pharmacy is to dispense medication in a quick and accurate manner. Accuracy is more important. Giving the customer the right medication and the right dosage can be a real matter of life or death. Some medicines have serious or fatal side effects when a patient combines them with other medicines or takes them in large doses. An eye for detail and staying alert will serve you well in a Pharmacy. These skills are essential whether youre distributing medication or putting patient information into the computer.


2. Computer Literacy

Most pharmacies today are connected to the internet. Computers allow medical providers to send prescriptions electronically. Likewise, computers also allow for easier storage of customer data, insurance information and inventory counts. You must be comfortable using a computer if you plan to work in a Pharmacy.


3. Strong Math And Science Skills

Although most of the work is done via computer, Pharmacy work requires the ability to perform calculations specific to medication. You must understand percentages, fractions and units of measurement. You also need a solid knowledge of chemistry, anatomy and physiology to understand how the body reacts to different medications. Pharmacists use these skills to calculate doses and study patient profiles, but theyre also useful skills for Pharmacy techs.

4. Ability To Operate Pill Counting Machines

In some pharmacies, the pill counting is still done by hand by the pharmacist. In most cases, the pharmacist delegates those duties to a certified Pharmacy tech who uses a pill counting machine to get the job done. The pill counting machines offer more accurate, more efficient counting. Operating the pill counting machines requires some training, both in school and on the job.

5. Good Interpersonal skills        

No matter how knowledgeable you are about medicine and the human anatomy, you must be able to interact well with the customers. Strong communication and interpersonal skills are essential to working successfully in health-related settings. You will interact with people every day, including your colleagues, patients, physicians and other healthcare professionals. People who work in a Pharmacy work as a team, so you must have a team-oriented approach to your work.
Pharmacists and Pharmacy techs are important members of the healthcare community. The jobs encompass a wide range of duties, from taking inventory, to dispensing medications and keeping records. With the essential skills listed above attention to detail, computer literacy, a strong background in math and science, familiarity with pill counting machines and excellent communication skills youll be more than prepared to tackle the various job duties. While you learn a great deal about the job in school, youll learn much more on the job when what youve studied combines with real-life experience.

Here are five must-have skills youll need to be successful:
Accurate manner: Accuracy is more important. Giving the customer the right medication and the right dosage can be a real matter of life or death. Some medicines have serious or fatal side effects when a patient combines them with other medicines or takes them in large doses. An eye for detail and staying alert will serve you well in a Pharmacy. These skills are essential whether youre distributing medication or putting patient information into the computer.

Bottom of Form
·       Entry of unqualified and non-meritorious students into the course.
·       Non focused and unspecialized way of learning.
·       Out dated curriculum and educational regulations.Lack of industrial and clinical exposure. Unskilled ways of practical and lab training in the institutes.
·       Research output from Indian educational labs rarely lead to commercialization and revenue generation.

NEED OF SKILL DEVELOPMENT IN                                                                                                   PHARMACEUTICAL CURRICULM

·       Priority over research in our universities.
·       Institutional base of research in India is extremely narrow serious research is limited to a few eliteinstitutes.
How to improve the situation?
           A system should be devised so that each and every student gets an opportunity to freely think and develop his skills to the maximum. Professionalism can be cultivated only through rational ways of thinking and performing. Students should come out with their ideas and suggestions in any aspect of education and especially be focused on innovative research. Most of our students are lacking an initial pull, which should be given by the teachers or the college. Students should also be trained to improve their presentation skills and their personality.
Coming to the educational aspect, much emphasis should be given to industrial and practical exposure. Clinical and practical training should be given more importance and made a part of the curriculum. Research oriented way of learning is more effective rather than mugging up a lot of theory. The knowledge of a Pharmacy student should be current and always the updation of his knowledge is necessary. He should be aware of what are the latest changes going in the field of Pharmacy. A student should learn to evaluate himself and try to continuously improve his knowledge levels.
The concept of the innovation system stresses that the flow of technology and information among people, enterprises and institutions is key to an innovative process. It involves the interaction between the elements, who indeed should turn an idea into a process, product or service resulting in national economic growth. Innovation ecosystems refer to the inter-organizational, political, economic, environmental and technological systems through which a milieu conducive to business growth is catalyzed, sustained and supported. Innovation ecosystem is an integrated approach for development. Innovation is something that generates value. Innovators must be challenged to produce solutions that society needs.
The role of universities in creating regional innovation ecosystems:
1.     Focus on grand challenges                           .
2.     The strong role of universities is crucial: Based on Knowledge Triangle, i.e. Synergy between research, education and innovation.
3.     Modernize the Triple Helix cooperation: University Industry Cities .
4.     Living labs and user-driven innovations: Focus on people and process development.
The present counselling system proves to be the first and foremost reason for the degradation of the profession in the country. The system creates a situation in which anyone who has money can get a seat in B. Pharm without the basic qualifications. The system has to be scrutinized and some regulations have to be made which assures that the meritorious students are entering into the profession. A centralized allotment procedure (CAP) is to be introduced to regulate the entry of students into the Pharmacy stream, which is purely based on the merit all throughout the country.
Quality is the key word for success of an institution. It is the essence for survival of a professional institution like Pharmacy. The vision and mission of the institution speak of quality as an ultimate goal. Recognizing the need to support and strengthen Pharmacy education worldwide, in November 2007, International Pharmaceutical Federation (FIP), in collaboration with the World Health Organization (WHO) and United Nations Educational, Scientific and Cultural Organization (UNESCO), formed the Pharmacy Education Taskforce. The Taskforce is a coordinating body of organizations, agencies, institutions, and individuals with the shared goal of catalyzing actions to develop Pharmacy education.
Reflect the vision for Pharmacy practice and education that has been developed The QA system should:
·       through profession wide consensus.
·       Allow appropriate input from all stakeholders, including students and the public.
·       Ensure that educational programs are evidence and competency-based, of high quality and meet the needs of the people, the pharmacists and their country.
·       Evaluate programmatic outcomes as well as institutional structures and processes.
·       Be transparent and be free of inappropriate influences and appearances of conflicts of interest in its development and implementation.
·       Promote and foster self-assessment and continuous quality improvement of educational institutions.
·       Be accountable to the appropriate governmental authorities.
The levels of hierarchy in a Pharmacy institution
Self-evaluation charts
Self-evaluation is an important part of TQM. Education is a customer focused industry. Every student should be capable of evaluating themselves for continuously improving their quality. They must have a thorough understanding of their strength and weakness. Self-evaluation charts (SEC) is a statistical data which is to be prepared by every student in the form of a graph or flow chart which is an indication of his progress in education related aspects. It seems to be a simple concept but it is a powerful tool. Preparation of SEC'S should be made compulsory from graduation level itself in all colleges. Periodic analysis of the chart should be done by the teacher in the presence of the student and discussions should be conducted and suggestions to improve should be put forward.
Applications of SEC's
·       A student gets the opportunity to evaluate himself.
·       It is an indication of a student's progress in academics or related activities.
·       It is also helpful to faculty members to analyze the progress of a student in academics.
E.g.: Recording of marks for a student in a particular session in seminars, assignments etc.
Seminars and presentations as powerful tools in quality education
Seminars and presentations turns about to be the most important tools in improving the quality of education in an institution. It is very important for a student to be skilled in making presentations and giving a seminar on a topic. Seminars should be given especially on the topics which are of current importance and recently under research. Seminars should be made compulsory from graduation level and should be a criterion for evaluation of the students.
·       It improves the understanding of the subject.
·       Researching attitudes of the students are developed.
·       Improves presentation, listening and reading skills of the students.
·       Inculcates professionalism.
·       Overview of subjects in an easy and comfortable way.
·       Interesting way of learning.
·       Information sharing becomes easier and the subject becomes more digestable to the students.
For graduation level: Minimum 5 seminars in an academic year.
For post-graduation level: Minimum 30 seminars in an academic year.
Clinical Pharmacy is one of the most important branches in Pharmacy. The present curriculum includes all the theoretical aspects of the particular subject but unfortunately the practical exposure is an absolute zero. This is the most important reasons for the professional degradation and discrimination of pharmacists in the country. We should include case studies in the graduation level in the subject of clinical Pharmacy which can enrich our practical exposure in the medical field and also help us to be recognized as a profession of prime importance in the health care system in India. Working with some case studies in the hospitals gives the students a clear idea of what happens in a health care system, how the theoretical part differs from the practical work outs. The actual treatment procedures in the clinical set up is far different from what we study in theory and is necessary that a clinical pharmacist should be in touch with all this procedures. The curriculum should be revised so that the student gets the opportunity to be accustomed with the actual situation in a clinic rather than mugging up chunks of theory.

An educational institution should provide the student with a stress free atmosphere for learning and developing his intellectual capabilities. But the situation is just the other way round in many institutions. The students are under stress due to the work over loads and inefficient time management, totally the academic life becomes horrible for them. Here comes the importance of counselling and its benefits to the students.
Benefits of counselling centre
·       Gives the students an opportunity to share their problems.
·       They can get solutions for their queries in academics and their personal life.
·       It can improve the confidence of the students.
·       Mental strengthening provides the stress free atmosphere for the student.
·       An overall improvement in the student intellects especially in academics.
·       Creating some smart professionals in the


·       This essay was written with aim of addressing the major issues related with Pharmacy education system in India and suggesting some basic level strategy shiftfor improving the situation. Revival of the Pharmacy education in India is the need of the hour and a master plan with an international perspective and its immediate implementation is the only solution.